Pacific Biosciences Of California (PACB) Total Non-Current Liabilities (2012 - 2026)

Pacific Biosciences Of California's Total Non-Current Liabilities history runs 14 years deep, the most recent figure standing at $772.0 million for Q1 2026.

• In Q1 2026, Total Non-Current Liabilities changed 0.37% year-over-year to $772.0 million; the TTM figure through Mar 2026 stood at $772.0 million (changed 0.37% YoY), while the FY2025 annual figure was $778.7 million, up 3.38% from the prior year.
• Total Non-Current Liabilities was $772.0 million for Q1 2026 at Pacific Biosciences Of California, down from $778.7 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $1.2 billion in Q4 2022 to a low of $753.3 million in Q4 2024.
• Historically, Total Non-Current Liabilities has averaged $947.5 million across 5 years, with a median of $1.0 billion in 2023.
• The sharpest annual moves came in 2022 and 2024: Total Non-Current Liabilities jumped 612.43% in 2022, then decreased 26.52% in 2024.
• A 5-year view of Total Non-Current Liabilities shows it stood at $1.2 billion in 2022, then fell by 14.77% to $1.0 billion in 2023, then decreased by 26.52% to $753.3 million in 2024, then increased by 3.38% to $778.7 million in 2025, then fell by 0.86% to $772.0 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $772.0 million (Q1 2026), $778.7 million (Q4 2025), and $767.1 million (Q3 2025), per Business Quant data.